Johan Cardoen

Protealis is an innovative company fostering the cultivation of sustainable plant-based proteins in Europe. We develop superior seeds and seed technologies for legume crops that are adapted to our local environment. By combining innovation in breeding and nitrogen fixation we create new opportunities for European farmers to help overcome Europe’s protein deficit and provide local sourcing options for the growing number of producers of meat and milk alternatives.

Confo Therapeutics’ unparalleled technology stabilizes functional conformations of GPCRs (G protein-coupled receptors) to uncover a wide range of previously inaccessible GPCRs as drug targets. This technology platform combined with the pharmacologic and biologic insight it provides, allows Confo to build a multi-indication pipeline of drug candidates with the potential to transform therapeutic outcomes for patients with severe illnesses lacking disease-modifying treatments. Confo Therapeutics was spun out of Vrije Universiteit Brussel (VUB) and VIB in 2015. Supported by international life-science focused investors and led by an experienced team of entrepreneurial professionals and scientists from successful biopharmaceutical companies, Confo Therapeutics benefits from the rich scientific and innovative ecosystem in Belgium. For more information: www.confotherapeutics.com

Aphea.Bio is dedicated to food security and ensuring a safe and healthy food chain. We aim to provide novel, science-based solutions to build the agriculture of the future: sustainable, reliable and profitable. Located in Gent, Belgium, we have a highly dedicated and qualified team of scientist and industry experts. Based on our unique high throughput R&D platform utilizing the untapped microbial space, we have been able to build a broad pipeline based on naturally occurring micro-organisms. Our solutions range from biostimulants to biocontrol, and focus mainly on row crops. Our key strength is flexibility, which allows us to quickly adapt to market needs and to provide tailored solutions. We believe that with a fresh and sincere spirit of innovation, result-driven science, and the courage to go off the beaten track, there is fertile ground to develop efficacious biological solutions to help complement or partially replace products in the major chemical indications.

We are a rapidly growing and transformative food and crop protection company developing a new generation of protein-based biocontrol solutions, shaping the future of sustainable and safe food supply. Based on our ground-breaking technology platform, Biotalys is developing a broad pipeline of effective and safe products with novel modes of action, addressing key crop pests and diseases across the whole value chain, from soil to plate. Biotalys’ unique protein-based biocontrols combine the high-performance characteristics of chemicals with the clean safety profile of biologicals, making them ideal crop protection agents for both pre- and post-harvest applications. We are on track to launch our first biofungicide in the USA in H2 2022, followed by subsequent market introductions globally. Biotalys was founded in 2013 as a spin-off from the VIB (Flanders Institute for Biotechnology) and is listed on Euronext Brussels. The company is based in the biotech cluster in Ghent, Belgium. More information can be found on www.biotalys.com.

argenx is a global immunology company committed to improving the lives of people living with severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx is translating immunology breakthroughs into a world-class portfolio of novel antibody-based medicines.

Protealis is an innovative company fostering the cultivation of sustainable plant-based proteins in Europe. We develop superior seeds and seed technologies for legume crops that are adapted to our local environment. By combining innovation in breeding and nitrogen fixation we create new opportunities for European farmers to help overcome Europe’s protein deficit and provide local sourcing options for the growing number of producers of meat and milk alternatives.

PBL Technology invests in, protects and promotes emerging innovations from public research sources worldwide - turning ideas into patented, scientifically validated and licensable technologies. PBL Technology establishes intellectual property protection, guides development through the proof-of-concept and prototype stage and licenses onwards to a wide variety of industry sectors. We market our technologies internationally and have regular contact with a very wide range of industrial customers, licensees and development partners.

Confo Therapeutics’ unparalleled technology stabilizes functional conformations of GPCRs (G protein-coupled receptors) to uncover a wide range of previously inaccessible GPCRs as drug targets. This technology platform combined with the pharmacologic and biologic insight it provides, allows Confo to build a multi-indication pipeline of drug candidates with the potential to transform therapeutic outcomes for patients with severe illnesses lacking disease-modifying treatments. Confo Therapeutics was spun out of Vrije Universiteit Brussel (VUB) and VIB in 2015. Supported by international life-science focused investors and led by an experienced team of entrepreneurial professionals and scientists from successful biopharmaceutical companies, Confo Therapeutics benefits from the rich scientific and innovative ecosystem in Belgium. For more information: www.confotherapeutics.com

Aphea.Bio is dedicated to food security and ensuring a safe and healthy food chain. We aim to provide novel, science-based solutions to build the agriculture of the future: sustainable, reliable and profitable. Located in Gent, Belgium, we have a highly dedicated and qualified team of scientist and industry experts. Based on our unique high throughput R&D platform utilizing the untapped microbial space, we have been able to build a broad pipeline based on naturally occurring micro-organisms. Our solutions range from biostimulants to biocontrol, and focus mainly on row crops. Our key strength is flexibility, which allows us to quickly adapt to market needs and to provide tailored solutions. We believe that with a fresh and sincere spirit of innovation, result-driven science, and the courage to go off the beaten track, there is fertile ground to develop efficacious biological solutions to help complement or partially replace products in the major chemical indications.